ESMO 2022 | Larotrectinib in patients with TRK fusion salivary gland tumours

David Hong, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses updated efficacy and safety results of larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor in patients with TRK fusion salivary gland tumors. In this update, larotrectinib continued to demonstrate rapid and durable efficacy with a favorable safety profile in patients with TRK fusion salivary gland tumors. These data highlight the importance of identifying NTRK gene fusions in this patient population. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.